spectinomycin has been researched along with flucytosine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fieker, DH; McHenry, MC | 1 |
| Plotkin, SA | 1 |
| Jackson, HO; Kumari, S; Mordaka, PM; Purton, S; Smith, AG; Taunt, HN | 1 |
2 review(s) available for spectinomycin and flucytosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Newer antibacterial and antimycotic drugs. Critical appraisal.
Topics: Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cephalosporins; Clindamycin; Flucytosine; Humans; Imidazoles; Penicillins; Rifampin; Spectinomycin; Sulfamethoxazole; Tetracyclines; Tobramycin; Trimethoprim | 1978 |
4 other study(ies) available for spectinomycin and flucytosine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Antibiotics, 1972.
Topics: Amino Sugars; Anti-Bacterial Agents; Bacteria; Candidiasis; Carbenicillin; Cephalosporins; Cryptococcosis; Drug Synergism; Flucytosine; Glycosides; Gonorrhea; Humans; Meningococcal Infections; Minocycline; Pseudomonas Infections; Spectinomycin; Sulfonamides; Tetracycline; Trimethoprim | 1972 |
CpPosNeg: A positive-negative selection strategy allowing multiple cycles of marker-free engineering of the Chlamydomonas plastome.
Topics: 3' Untranslated Regions; Aminoglycosides; Biomarkers; Chlamydomonas; Chlamydomonas reinhardtii; Chloroplasts; Cytosine Deaminase; Escherichia coli; Flucytosine; Spectinomycin; Transformation, Genetic | 2022 |